Rubius Therapeutics to Announce Third Quarter 2018 Financial Results

CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, plans to report third quarter 2018 financial results on Tuesday, November 13, 2018.

The company will not be conducting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics

Rubius Therapeutics is a biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.

Media Contact:  Dan Budwick 1AB, Inc. +1 (973) 271-6085 [email protected] 

Investor Contact: Lori Melançon Vice President, Corporate Communications and Investor Relations +1 (617) 229-6122 [email protected] 

Source: Rubius Therapeutics

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• GitLab’s second-quarter revenue jumps 21% as AI demand drives bookings
• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Stifel Starts Tower Semiconductor (TSEM) at Buy, Top Pick